First-Phase Insulin and Amylin after Bariatric Surgery: A Prospective Randomized Trial on Patients with Insulin Resistance or Diabetes after Gastric Bypass or Sleeve Gastrectomy

What Was Tested

The paper reports a study of Amylin (Islet Amyloid Polypeptide) in the context of insulin resistance, prediabetes & type 2 diabetes, published as a randomized controlled trial.

Most patients with severe obesity show glucose intolerance.

Early after sleeve gastrectomy (LSG) or gastric bypass (LRYGB), a marked amelioration in glycemic control occurs.

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, both men and women.

Sixteen morbidly obese patients with severe obesity and different degrees of insulin resistance were randomized to LSG or LRYGB, and islet cell functions were tested by intravenous glucose and intravenous arginine administration before and 4 weeks after surgery.

How the Study Was Run

The researchers set it up as a randomized study.

Because people in this Amylin (Islet Amyloid Polypeptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

University of Basel Hospital and St.

What Was Measured

The subject headings attached to it are Bariatric Surgery, Diabetes Mellitus, Fasting, Gastrectomy, Gastric Bypass, Insulin and Insulin Resistance.

The authors tagged it with the keywords First-phase insulin, Intravenous arginine stimulation, Intravenous glucose stimulation and β-Cell function.

What This Means in Plain Language

The paper is a randomized study of Amylin (Islet Amyloid Polypeptide) in people with insulin resistance, prediabetes & type 2 diabetes.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2020 (Obesity facts), a journal based in Switzerland.

More context: the Amylin (Islet Amyloid Polypeptide) compound page, Insulin resistance, prediabetes & type 2 diabetes research.